Australia vaccine funding, Sinopharm’s global push, ECB accelerates stimulus

Canberra is contemplating investing in a A$1bn biopharmaceutical plant to reduce its dependence on imports of critical medicines, China’s state-backed pharmaceutical group, Sinopharm, wants more governments to buy its Covid-19 vaccine, and Spain is set to become the first EU country to amend its laws to give some gig economy workers employee rights. Plus, the FT’s markets editor, Katie Martin, explains why the European Central Bank will accelerate its bond buying programme.  

Australia considers funding vaccine maker to curb reliance on imports

https://www-ft-com.ezp-prod1.hul.harvard.edu/content/483e6275-6d27-433c-9cbc-6918f2c916c6?edit=true

Spain to grant gig delivery workers employee rights

https://www-ft-com.ezp-prod1.hul.harvard.edu/content/73be294b-a43d-4387-aced-7b5cb0d91007?

Sinopharm faces battle to turn Covid vaccine into a global success

https://www-ft-com.ezp-prod1.hul.harvard.edu/content/99c7a9de-fc11-45ab-890b-f6733ccb4186

ECB pledges to step up pace of stimulus to counter market sell-off

https://www-ft-com.ezp-prod1.hul.harvard.edu/content/bd7ccf1d-3b07-4f13-9a14-68692ef84e95

Rise of the retail army: the amateur traders transforming markets

https://www-ft-com.ezp-prod1.hul.harvard.edu/content/7a91e3ea-b9ec-4611-9a03-a8dd3b8bddb5

See acast.com/privacy for privacy and opt-out information.

View our accessibility guide.